Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Geovax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus (HIV), as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeoVax Labs advances cancer therapies and COVID-19 vaccine development

GeoVax Labs showcased advancements in cancer therapies and COVID-19 vaccine development, underlining a commitment to innovation and global healthcare improvement.
While facing financial challenges due to increased R&D expenses and net loss, GeoVax's strategic strengths in vaccine development and clinical trials offer promising opportunities for growth.
The completion of the Gedeptin trial, ongoing Phase II trials for CM04S1, and plans for future vaccine developments position GeoVax for impactful contributions to healthcare.

GeoVax Labs reports Q2 loss, progresses in key trials

GeoVax's Q2 performance reflects ongoing investment in R&D and progress in key clinical trials.
The company's strengths lie in securing funding, commitment to innovation, and vaccine differentiation.
Challenges include recruitment issues, funding needs, and uncertainties in the pipeline.
Opportunities exist in fundraising, vaccine development, expanding indications, and optimizing clinical trials.

GeoVax Labs reports Q3 progress with vaccine trials and financial challenges

GeoVax Labs' Q3 performance reflects a mix of achievements and challenges, with a focus on advancing vaccine candidates and managing financials. The company's strengths in innovation and clinical trial strategies position it well for future growth opportunities through partnerships and regulatory advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Phase 2 Clinical Trials Advance for COVID-19 and Immuno-Oncology

GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update

ATLANTA, GA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after the market close on Wednesday, November 9, 2022.

GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022

American Virtual Cloud Technologies

Faraday Future Intelligent Electric

Here's what you need to know about trading penny stocks today The post Trending Penny Stocks You Need to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks You Need to Watch This Week

Grab Holdings Ltd

Use these strategies for investing in penny stocks in 2022 The post How to Find Penny Stocks to Buy This Month, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Find Penny Stocks to Buy This Month, 3 Tips

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine (GEO-CM04S1) and Phase 1/2 Clinical Trial for Advanced Head and Neck Cancer (Gedeptin ® )

GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Nicole Lemerond, CFA, Brings Healthcare Finance Expertise to the GeoVax Board

GeoVax Announces Addition to Its Board of Directors

GeoVax Labs (NASDAQ: GOVX ) recently released its second-quarter 2022 financial results. Some investors might object to GeoVax's net earnings loss.

GeoVax Labs Stock Is a Monkeypox Meme Play for Bold Traders

Applied DNA Sciences

Chimerix

iShares Genomics Immunology and Healthcare ETF

SIGA Technologies

Tonix Pharmaceuticals Hld

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

GeoVax Labs (NASDAQ: GOVX ) stock has gone parabolic and it's easy to see why. As the extent of the 2022 monkeypox outbreak keeps getting worse, this virus continues to be at the top of the headlines.

GeoVax Labs Stock Has a Lot More Than Hype Behind Its Recent Surge

GeoVax has multiple routes to go in terms of Covid-19 vaccine development; use of GEO-CM04S1 for Covid-19 in immunocompromised patients and as booster, plus GEO-CM02 as pan-coronavirus vaccine. GeoVax has the potential to possibly advance GEO-CM04S1 as a preventative Monkeypox vaccine. Successful prevention of Monkeypox in non-human primate models has been shown in peer-reviewed journal using MVA.

GeoVax: Possible Vaccine Advancements In 2 Big Indications

The White House has declared monkeypox a public health emergency. Within the last two weeks, California, New York and Illinois making the same declaration already, and many other states are sounding the alarm.

3 Monkeypox Stocks to Buy as Biden Declares Public Health Emergency

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants David Dodd – Chairman and Chief Executive Officer Mark Reynolds – Chief Financial Officer Mark Newman – Chief Scientific Officer John Sharkey – Head, Business Development Conference Call Participants Jason McCarthy - Maxim Group Jeff Kraws - Crystal Research Kumarguru Raja - Brookline Capital Markets Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2022 Corporate Update Call. I'm Andrew with Chorus Call and will facilitate today's call.

GeoVax Labs, Inc. (GOVX) CEO David A. Dodd on Q2 2022 Results - Earnings Call Transcript

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology

GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update

The stock price of Geovax Labs (GOVX) surged by 42.86% today. This is why.

Geovax Labs (GOVX) Stock: Why It Climbed 42.86% Today

Virax Biolabs Group Ltd

Monkeypox stocks are rallying amid worries about a shortage of vaccines for the illness in the U.S. Additionally, in recent days, New York state, New York City and San Francisco have issued emergency orders related to monkeypox. Several related names rallied in pre-market trading today and are still up since the market opened this morning.

Monkeypox Stocks GOVX, VRAX, SIGA Rocket on Vaccine Shortage Fears

Clarus Therapeutics Holdings

Verb Technology Company Inc

Check these tips out for your penny stocks buy list right now The post Top Tricks for Trading Penny Stocks Right Now, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Tricks for Trading Penny Stocks Right Now, 3 Tips

Allena Pharmaceuticals

Applied Blockchain Inc

Here's what you need to know about buying penny stocks on July 29th The post Hot Penny Stocks to Watch Before Market Open on July 29th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch Before Market Open on July 29th

ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of a peer-reviewed animal efficacy study of its modified vaccine Ankara (MVA) vectored vaccine against Sudan ebolavirus (SUDV). The study was published in Nature Partner Journals (NPJ) Vaccines .

GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization

Imperial Petroleum

Here's what you need to know about buying penny stocks on July 27th The post What to Know About Buying Penny Stocks on July 27th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on July 27th

Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time

GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update

VistaGen Therapeutics

Here's what you need to know about trading penny stocks on July 26th The post What to Know About Buying Penny Stocks on July 26th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on July 26th

If you thought monkeypox was a fad, you might want to reconsider.

Hot Penny Stocks To Watch As Monkeypox Gets WHO GHE Designation

Emergent BioSolutions

Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. The post Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency appeared first on InvestorPlace.

Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency

GOVX stock is soaring in early trading after WHO declared monkeypox a global health emergency over the weekend. The post Why Is GeoVax (GOVX) Stock Up 90% Today?

Why Is GeoVax (GOVX) Stock Up 90% Today?

Blue Hat Interactive Entertainment Technology

Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy in July?

News for Geovax Labs Stock (GOVX)